HC Wainwright Issues Optimistic Outlook for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Olema Pharmaceuticals in a report issued on Monday, March 16th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their prior estimate of ($0.51). HC Wainwright currently has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.29) EPS, FY2028 earnings at ($1.87) EPS, FY2029 earnings at ($1.39) EPS and FY2030 earnings at ($0.64) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01.

OLMA has been the subject of several other research reports. Piper Sandler started coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. UBS Group began coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued a “buy” rating and a $45.00 price objective for the company. Guggenheim dropped their target price on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus began coverage on Olema Pharmaceuticals in a report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.22.

Olema Pharmaceuticals Stock Down 9.3%

NASDAQ:OLMA opened at $15.06 on Wednesday. Olema Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $36.26. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -8.10 and a beta of 1.92. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $23.81 and its two-hundred day moving average price is $18.73.

Insiders Place Their Bets

In other news, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shane William Charles Kovacs sold 100,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the completion of the transaction, the insider owned 139,727 shares in the company, valued at $4,014,356.71. This trade represents a 41.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 805,501 shares of company stock worth $23,003,832 over the last three months. 16.36% of the stock is currently owned by corporate insiders.

Institutional Trading of Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of OLMA. EverSource Wealth Advisors LLC boosted its holdings in Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares during the period. Torren Management LLC acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $88,000. Nisa Investment Advisors LLC grew its position in Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after acquiring an additional 1,169 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings surprised slightly to the upside — Olema reported ($0.50) EPS vs. consensus ($0.51), which triggered positive investor reaction and immediate share strength. Press Release OLMA Stock Jumps After Q4
• Positive Sentiment: HC Wainwright raised near‑term and multi‑year EPS forecasts across 2026–2030 (slightly less negative EPS), reiterated a “Buy” rating and kept a $38 price target — signaling improving economics expectations for the company. This analyst lift supports further upside sentiment. Analyst Note
• Positive Sentiment: Citigroup raised its price target sharply (from $60 to $62) and maintains a buy view — a material, bullish institutional price-target move that can draw attention from momentum and institutional buyers. Benzinga: Citigroup
• Positive Sentiment: Large external interest tied to Olema’s breast‑cancer drug: reports note a ~$68.7M wager related to the program targeting a 2027 launch, which underscores investor confidence and potential financing/support for commercial plans. Globe and Mail: $68.7M Bet
• Positive Sentiment: Clinical visibility: Olema (via Olema Oncology) will present preclinical data for palazestrant and OP‑3136 at AACR 2026 — continued scientific disclosure can reduce clinical uncertainty and support longer‑term valuation. Business Insider: AACR Presentation
• Negative Sentiment: Guggenheim trimmed its price target (from $40 to $38) though it kept a “Buy” rating — a slight headwind as some investors may see this as less bullish relative to higher targets. Benzinga: Guggenheim

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.